Apollo Hospitals Enterprise Limited (APOLLOHOSP) Fair Value & Analysis

Healthcare · IN · Market cap ₹1.3T

A solid business, but screening 67% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹4,187). The favourable scenario is already priced in.
• The model range is unusually wide (₹1,472 to ₹4,187). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 3, 2026.

How to read this chart

60‑month range ₹2,772 – ₹8,986 · fair‑value band ₹1,472 – ₹4,187 · the ₹8,955 price screens above the ₹2,955 fair value. Dashed = 300-day average. As of Aug 3, 2026.

Which stocks are undervalued right now? Check free Discover now →

Analysis

Apollo Hospitals Enterprise Limited (APOLLOHOSP) currently trades at ₹8,955, while our model-based Fair Value estimate is ₹2,955, implying the stock looks roughly 67.0% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Apollo Hospitals Enterprise Limited generated revenue of ₹252B at a net margin of 7.7%. Revenue grew 18.1% year over year. It earns a return on equity of 21.5%. Net debt stands at ₹48.5B. Fundamentals as of Aug 3, 2026

Our scenario range runs from ₹1,472 (bear case) to ₹4,187 (bull case); at ₹8,955, the current price sits above that range. The share trades about 2% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -67%, APOLLOHOSP screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹3,078) versus Asset-Based (₹441.75). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Apollo Hospitals Enterprise Limited, together with its subsidiaries, engages in the provision of healthcare services in India and internationally. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments.

Full company description

Apollo Hospitals Enterprise Limited, together with its subsidiaries, engages in the provision of healthcare services in India and internationally. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, orthopedics, oncology, neurosciences, emergency, robotic surgery, and transplants; and cardiology, neurology, gastroenterology, dermatology, ophthalmology, pediatric, endocrinology, gynecology, urology, nephrology, pulmonology, rheumatology, neurosurgery, radiology, plastic-surgery, neonatology, vascular-surgery, psychiatry, dentistry, ear, nose, and throat care, as well as genomic medicines. The company also provides other services, such as project consultancy, health insurance, medical colleges, medvarsity for e-learning, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, dialysis centers, cradle and fertility centers, diabetes management centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. Further, the company engages in the business of bio-banking of tissues. It serves through national retail healthcare centers and genomics institutes, as well as Apollo 24/7, a digital health mobile platform; and www.apollopharmacy.in, an online pharmacy. The company was incorporated in 1979 and is based in Chennai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Apollo Hospitals Enterprise Limited reported revenue of ₹252B in FY2026 versus ₹145B in FY2022, a compound +14.8%/yr. Reported net income was ₹19.4B in FY2026, compounding +16.5%/yr from FY2022.

APOLLOHOSP screens 67% overvalued. Compare with HCA Healthcare, Inc →

Peer Group

Medical Care Facilities · 270 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 3, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.